HDAC8 is a therapeutic target with great promise for
breast cancer.
Here, we reported a novel compound corallorazine D from Nocardiopsis sp. XZB108, selectively inhibited HDAC8 (IC50 = 0.90
± 0.014 μM), suggesting that it may be a promising nonhydroxamate
HDAC8 inhibitor. Upon additional modifications of corallorazine D,
a candidate compound 5k, demonstrated remarkable inhibitory
potency against HDAC8 (IC50 = 0.12 ± 0.01 nM), 89-fold
superior to PCI-34051. The selectivity of 5k was at least
439-fold, superior to corallorazine D, confirming the efficacy of
our modifications. In an orthotopic mouse model of breast cancer, 5k displayed nearly 4-fold superior antitumor activity than
SAHA. Furthermore, 5k triggered antitumor immunity by
activating T cells. Treatment with 5k significantly increased
the proportion of M1 macrophages and decreased the proportion of M2
macrophages (M1/M2 ratio = 2.67 ± 0.25). 5k represents
a promising compound for further investigation as a potential treatment
for breast cancer.